Although pathogenic autoimmune cells have been intensively investigated as the targets of Qa-1-mediated antigen-specific therapy, myelin sheath (i.e. the tissue that is attacked by one’s own immune system in MS patients) has been the target of most antigen-specific therapies5. The gene discussed is HLA-E; the disease is myeloid sarcoma.